Anika Q3 revenue up 25% to $39.5M, net income $0.6M; cuts FY2021 revenue growth outlook to 9-11% from 11-14%

Anika Therapeutics, Inc.

2021-Q3 EPS reported $0.68 revenue$111,973,000

Revenue $39.5M (+25% YoY); Joint Pain Management up 42% to $26.2M.
Net income $0.6M ($0.04 diluted) vs net loss $6.4M a year ago; adjusted net income $0.8M ($0.05 diluted).
Adjusted EBITDA $5.8M vs $4.9M; operating cash flow $2.1M; cash $91.0M.
FY2021 revenue growth guidance revised to 9-11% (previously 11-14%) due to COVID Delta variant headwinds.
Launched WristMotion Total Wrist Arthroplasty; received 510(k) clearance for Tactoset hardware augmentation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.